<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796453</url>
  </required_header>
  <id_info>
    <org_study_id>ILE632-I001</org_study_id>
    <nct_id>NCT05796453</nct_id>
  </id_info>
  <brief_title>Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity &amp; Clareon PanOptix</brief_title>
  <official_title>Long-term Evaluation of Safety and Performance of Clareon Presbyopia-Correcting Intraocular Lenses (IOLs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety&#xD;
      and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix&#xD;
      Toric IOLs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be recruited from a population that has already undergone lens implantation.&#xD;
      Retrospective data will be collected from the pre-operative and surgical visits and any&#xD;
      safety outcomes reported prior to enrollment. Prospective data will be collected from time of&#xD;
      study enrollment through the Year 3 follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2023</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Binocular Best Corrected Distance Visual Acuity (BCDVA) at each prospective visit</measure>
    <time_frame>Up to Year 3</time_frame>
    <description>BCDVA will be assessed at a distance of 4 meters using letter charts and recorded in logarithm Minimum Angle of Resolution (logMAR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>Up to Year 3</time_frame>
    <description>Protocol-specified ocular adverse events will be assessed at each prospective visit and include the following:&#xD;
Cystoid Macular Edema (CME)&#xD;
Hypopyon&#xD;
Endophthalmitis&#xD;
Lens dislocation&#xD;
Pupillary Block&#xD;
Retinal Detachment&#xD;
Secondary Surgical Interventions (Explantation/exchange/repositioning)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Device Deficiencies</measure>
    <time_frame>Up to Year 3</time_frame>
    <description>Device deficiencies will be assessed at each prospective visit. Examples include the following:&#xD;
Failure to meet product specifications (e.g., incorrect IOL power)&#xD;
IOL defect&#xD;
Broken IOL optic&#xD;
Broken IOL haptic&#xD;
Scratched IOL optic&#xD;
Unsealed device packaging&#xD;
Suspected product contamination&#xD;
Lack of performance</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Aphakia</condition>
  <condition>Astigmatism</condition>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Clareon Vivity IOL - Non Toric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon Vivity IOL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clareon Vivity IOL - Toric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with Clareon Vivity IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon Vivity IOL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clareon PanOptix IOL - Non Toric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a non-toric Clareon PanOptix IOL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clareon PanOptix IOL - Toric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation with Clareon PanOptix IOLs in both eyes 3-6 months prior to enrollment, with at least one of the eyes implanted with a toric Clareon PanOptix IOL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon Vivity IOL - Non Toric</intervention_name>
    <description>Spherical extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.</description>
    <arm_group_label>Clareon Vivity IOL - Non Toric</arm_group_label>
    <other_name>Models CNWET0, CCWET0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon Vivity IOL - Toric</intervention_name>
    <description>Toric extended vision IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.</description>
    <arm_group_label>Clareon Vivity IOL - Toric</arm_group_label>
    <other_name>Models CNWET3, CNWET4, CNWET5, CNWET6, CCWET3, CCWET4, CCWET3, CCWET3-T6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon PanOptix Trifocal IOL - Non Toric</intervention_name>
    <description>Spherical trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed.</description>
    <arm_group_label>Clareon PanOptix IOL - Non Toric</arm_group_label>
    <other_name>Model CNWTT0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clareon PanOptix Trifocal IOL - Toric</intervention_name>
    <description>Toric trifocal IOL implanted in the capsular bag of the eye for the visual correction of aphakia and for reduction of residual refractive astigmatism in adult patients in whom a cataractous lens has been removed.</description>
    <arm_group_label>Clareon PanOptix IOL - Toric</arm_group_label>
    <other_name>Models CNWTT2, CNWTT3, CNWTT4, CNWTT5, CNWTT6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Subject or legally authorized representative must be able to understand and sign an&#xD;
             approved Informed Consent Form.&#xD;
&#xD;
          -  Subject must have had bilateral implantation of Clareon Vivity, Clareon Vivity Toric,&#xD;
             Clareon PanOptix, or Clareon PanOptix Toric IOLs between 3-6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Subject must have a documented medical history and required pre-operative baseline&#xD;
             information available for retrospective data collection.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently participating in another investigational drug or device study.&#xD;
&#xD;
          -  Subject has had corneal refractive surgery after Clareon Vivity, Clareon Vivity Toric,&#xD;
             Clareon PanOptix, or Clareon PanOptix Toric IOL implantation.&#xD;
&#xD;
          -  Subject is pregnant at the time of enrollment.&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Lead, Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alcon Call Center</last_name>
    <phone>1-888-451-3937</phone>
    <email>alcon.medinfo@alcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

